I N T R O D U C T I O N
Kidney biopsy is accepted worldwide as a standard and safe approach to study renal pathology [1] . Despite its invasiveness and poor compliance, renal biopsy makes it possible to establish a diagnosis, categorize the disease itself, provide prognostic information regarding the clinical outcome and determine an appropriate therapeutic intervention.
Nevertheless, renal biopsy has some limitations as a diagnostic tool, due to the complexity and heterogeneity of histological lesions. Different classifications have been proposed for some renal diseases, such as IgA nephropathy (IgAN) [2] or lupus nephritis (LN) [3] . However, classifications based on histological lesions and clinical features need periodic updates.
Recently, high-throughput technologies have revolutionized the approach to basic and clinical research, changing the focus from the single gene, protein and/or metabolite to the whole genome, proteome and metabolome. The integrated analysis of all these data could potentially allow investigators to assess personalized therapeutic strategies on the basis of individual pathological profiles [4] . Among high-throughput technologies, transcriptomics is probably the closest to clinical application in kidney biopsies.
Transcriptomics scan the complete set of RNA transcripts (the transcriptome) encoded by cells or tissues, and it reflects the gene-expression profile at a specific time or under a specific condition. Next-generation sequencing technology (RNA-Seq), is the latest technology in the transcriptomics field [5] , but most of the available data are based on DNA microarray technologies [6, 7] .
In this emerging era of personalized medicine, precise mechanism-based diagnosis is essential to characterize glomerular diseases and to deliver targeted therapies to individual patients. This review aims to summarize state-of-the-art transcriptomics in kidney biopsies and to analyse the specific contribution of this molecular approach in the emerging field of precision medicine.
M A T E R I A L S A N D M E T H O D S

Search strategy
An electronic search of PUBMED and MEDLINE was conducted (dates searched ranged from 1996 to November 2016) using terms relevant to this review, without language restriction (Supplementary data, Table S1 and Appendix). In addition, journals, conference proceedings and current awareness alerts were hand-searched. Two authors (I.N. and F.P.S.) independently screened the records by title, abstract and full text to identify eligible publications that fulfilled the inclusion criteria. The only publications considered were those that assessed microarray studies regarding primary [minimal change disease (MCD), focal segmental glomerular sclerosis (FSGS) and membranous nephropathy (MN)] and secondary [LN and diabetic nephropathy (DN)] glomerulopathies as defined by the authors. Studies of molecular biology that did not consider transcriptomics were excluded.
R E S U L T S
Study selection
First, 716 records were identified through the database searches. Hand-searching identified another 21 articles, which were also included ( Figure 1 ). Some records were excluded for duplication or considering only clinical studies without kidney biopsy transcriptomics in other organs or biological fluids. Then, 383 articles that were dedicated to other kidney diseases or other omics were excluded. Therefore, this review ultimately included 19 relevant studies on transcriptomics in kidney biopsy from human and mouse models related to primary and secondary glomerulopathies.
Transcriptomics in kidney biopsy
A DNA microarray is an assembly of thousands of genespecific probe sets fixed in high-density arrays on a chip with a small surface area. The probes hybridize with complementary DNA (cDNA) from the sample of interest, and the degree of hybridization is measured by signal intensity, which quantifies the transcript abundance [8] . Currently, several protocols are available for whole gene-expression studies, technologies have become more robust, results are reproducible and costs have decreased considerably. Many software tools exist to analyse microarray data. Although the software is intuitive and userfriendly, expert operators are required to avoid false results. Published microarray studies remain freely available to the scientific community.
Because the quality and reproducibility of data depend on the quantity and integrity of the nucleic acids obtained, the initial material is a crucial element in transcriptomics.
Freezing is currently accepted as the best method to preserve both nucleic acid and protein quality after extraction from tissue. An acceptable degree of RNA preservation is achieved by immediate snap-freezing in liquid nitrogen, followed by storage at À80 C. However, the variation in time taken to reach FIGURE 1: PRISMA flow diagram of the review process.
Transcriptomics in renal biopsy freezing point causes significant problems in the yield and quality of mRNA. The feasibility of renal tissue for microarray analysis has been demonstrated in glomeruli isolated from frozen biopsy sections in several renal diseases by using RNAlater TM to allow efficient preservation of mRNA during storage and microdissection procedures [8] .
In the nephrology field, formalin-fixed paraffin-embedded (FFPE) biopsy is widely used to preserve tissue in clinical laboratories. FFPE tissue represents the greatest stock of archived samples. However, it is not the first choice for global geneexpression profiling, due to chemical alteration and fragmentation of nucleic acids in the double strand AT-rich region of DNA [9] during fixation and inclusion processes. Similarly, the quantity and quality of RNA change with the period of storage [10] . Finally, storage conditions (temperature, humidity and light exposure) contribute to effects on nucleic acid extraction results in FFPE blocks. For all these reasons, many transcriptomic studies have been conducted using fresh tissue; however, the most important limitation is the low number of cases included in studies.
Despite variability in tissue processing and collection, recent publications have demonstrated that FFPE tissue blocks stored for up to 24 years may be used to extract adequate and suitable DNA and RNA [11, 12] , and some successes have been reported in kidney biopsy. In 2010, Hodgin et al. carried out a transcriptomic study, beginning with FFPE renal biopsies (ranging from 5 to 24 years) in which they assessed the reproducibility difference between frozen and FFPE-matched samples. As expected, they demonstrated a profound difference in RNA quality. The FFPE samples had highly fragmented total RNA with no ribosomal peaks. Nevertheless, comparison of the gene-expression profiles of glomeruli from FFPE versus frozen kidney sections from the same patient revealed high correlation rates, demonstrating that glomerular gene-expression profiles from FFPE are comparable with frozen tissue [13] .
Transcriptomics in glomerular diseases
In recent years, researchers have made considerable progress in understanding the pathogenesis of primary glomerular diseases by using renal biopsies for high throughput analysis. Different multicentre studies have been organized worldwide in recognition of the necessity of large cohorts and standardized collection protocols for samples and clinical data. The Consortium of European Renal cDNA Bank (ERCB), of which the authors are members, is a successful example of a renal cDNA biopsy bank. The collaboration of European renal research centres was initiated in the early years of the 21st century. In participating centres, second specimens of each kidney biopsy were collected and processed for molecular analysis, following the working protocol for RNA preservation [8] . Informed consent and clinical parameters were collected on a standardized data sheet from each patient [14] .
More recently, the North American Multicenter Nephrotic Syndrome Study Network (NEPTUNE) collected kidney biopsy samples from 450 adults and children with different glomerular diseases, such as MCD, FSGS and MN, to study correlations between clinical and laboratory parameters, and renal transcriptome [15] . ERCB and NEPTUNE are two significant examples of the multidisciplinary and multicentre approach that is opening the way towards precision medicine.
MCD and FSGS. MCD and FSGS are primary causes of nephrotic syndrome, particularly in children. Although the pathogenesis of MCD is still unknown, there is considerable evidence that it is an immune-mediated disease. For this reason, most transcriptomic studies into MCD have been obtained from the cDNA of T-cell-enriched peripheral blood mononuclear cells [16, 17] .
First, Hodgin et al. [13] compared the gene expression of glomeruli from MCD with normal glomeruli from living donors. They evidenced differentially expressed genes that, when analysed by gene ontology, revealed two categories of transcripts leading to amino acids and derivative metabolic processes and cell adhesion (Table 1) . Then, Sanchez-Niño et al. [18] demonstrated that there was principally an upregulation of fibroblast growth factor-inducible 14 (Fn14) and monocyte chemotactic peptide-1 (MCP-1) associated with NFjB activation. These data have been considered a response from damaged podocytes to a non-immune stimulus, such as proteinuria.
FSGS is a heterogeneous condition that may result from different pathogenetic mechanisms and it is characterized by five histological subtypes, depending on podocyte injury. Schwab et al. [19] conducted microarray studies in archived frozen kidney biopsies from 10 patients with FSGS ( Table 1) . The results were compared with normal kidney tissue obtained after nephrectomy. They found 534 differentially expressed genes, of which 151 are involved in the gene-expression pattern of FSGS characterized by nephrotic syndrome (overexpression of thrombospondin, versican and collagen genes). Analysis also showed significant changes of gene expression in FSGS with renal insufficiency. The study confirmed the specific participation of the WT1, NPHS1 and MYH9 genes ( Table 1) .
Since the site of the primary injury in FSGS is the glomerulus, Bennett et al. studied glomerular-specific changes in gene expression [20] . They used laser-capture microdissection to isolate glomeruli from frozen kidney biopsies of FSGS patients and 10-15 glomeruli with similar histological features (mild, moderate and severely affected glomeruli) were pooled for RNA isolation. Microarray analysis identified 128 genes with a fold change >5 in expression and a distinct trend for geneexpression changes characterized by the different grades of affected glomeruli. Unfortunately, the low RNA yield did not allow further experiments, and validation was limited to immunohistostaining for CXCL1 and CD24 genes. However, microarray analysis provided an extended set of modulated genes and pathways associated with FSGS, such as SOX9, COL1A1, ostepontin and TGF-b signalling, which may be considered candidate targets for future therapeutic strategies (Table 1) . Later, Hodgin et al. [13] identified a specific glomerular profile using microdissected glomeruli from the FFPE renal biopsies of 21 patients with either an FSGS or MCD diagnosis. Data were validated by quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistological analysis. As discussed earlier, the reproducibility between matched frozen and FFPE samples was assessed. They found that MCD was not differentiated from normal kidney tissue. Conversely, comparing FSGS with controls, 405 probe sets were significantly expressed in isolated glomeruli. Interestingly, podocyte-specific genes, SOX9 and COL1A1, were up-regulated along with other genes involved in podocyte junctions. Moreover, Hodgin et al. [13] compared two different variants of FSGS lesions, and they found a distinctive molecular pattern of collapsing FSGS characterized by dysregulated podocyte genes (AIF1, DSP, CCD91). The overexpression of parietal epithelial cell genes supports their important role in repopulating the glomerular capillaries denuded of injured podocytes. Moreover, the investigators identified a molecular characteristic profile for glomerular lesions in different forms of FSGS.
Sanchez-Niño et al. [18] studied gene expression on laser microdissected glomeruli from FFPE renal biopsies (seven MCD, eight FSGS) compared with nine histological normal renal biopsies. The expression of Fn14 and MCP-1 mRNA were up-regulated in FSGS and MCD, and there was a correlation between the expression of these two transcripts. Moreover, tumour necrosis factor-like weak inducer of apoptosis (TWEAK) operated in collaboration with Fn14 to induce podocyte damage. Interestingly, these data were confirmed in a large independent transcriptomics dataset obtained from frozen tissue stored in RNAlater TM (18 FSGS, 14 MCD, 21 MN and 32 living donors) [18] . In conclusion, this pathway could be considered a potential target for therapy.
The therapy protocol for both MCD and FSGS includes corticosteroids and immunosuppressive drugs. Different responses to therapy often occur in patients with MCD or FSGS.
Differences in the treatment responses and prognosis support the importance of a diagnostic biomarker to differentiate between these diseases. Tong et al. [21] compared the geneexpression profiles of microdissected glomeruli obtained from fresh renal tissue of patients with a diagnosis of either FSGS or MCD in a Chinese population (Table 1) . They identified differentially expressed genes primarily involved in spermatogenesis, gamete generation, regulation of muscle contraction, response to unfolded protein, cell proliferation and skeletal system development in FSGS patients compared with MCD patients. Among these genes, the membrane metallo-endopeptidase gene was down-regulated, probably due to an injury to the podocytes. Other genes and specific pathways for FSGS were identified as potential new biomarkers for targeted therapy. The very small sample size (six FSGS and five MCD) and the absence of a control group represent serious limitations in this study.
Summarizing these data, we can outline that the damaged podocytes in MCD are characterized by dysregulation of genes involved in cell adhesion (Fn14 and MCP-1) that are associated with other genes responsible for cell proliferation (WT1, NPHS1, NYH9), motility and migration (SOX9, COL1A1) in FSGS. These genes may be considered potential targets for monitoring specific molecular therapies indicated by the systems pharmacology.
MN. MN is an antibody-mediated autoimmune glomerular disease with the presence of immune deposits in the glomerular capillary wall. The secretory phospholipase A2 receptor was identified by western blot as the target of autoantibodies in patients with MN [22] . This finding has had a huge clinical impact, with consequent development of recombinant proteins and antibodies [23, 24] . Transcriptomics on MN has been conducted only in rat models with passive Heymann nephritis (PHN). Hauser et al. identified 54 differently expressed genes compared with a normal rat kidney [25] . The number of transcripts increased to 225 following the onset of proteinuria. Among these genes, transgelin was the most up-regulated gene. These data were validated by the presence of increased transgelin staining in diseased glomeruli. Thus, this gene may provide a potential novel therapeutic target in PHN nephritis. Transcriptomic data in human MN have not yet been published.
IgAN. IgAN is characterized by the overproduction of hypogalactosylated IgA1. The formation of anti-glycan-specific IgG and IgA antibodies recognizing these hypogalactosylated IgA1 molecules causes the deposition of immune complexes in the glomerular mesangium [26] . The proliferation of mesangial cells and the expanded mesangial matrix are caused by the deposition of circulating IgA1-IgG immune complex in the kidneys of patients with IgAN. Ebefors et al. [27] studied the distribution of gene and protein expression of proteoglycans, which are an important component of the mesangial matrix in microdissected glomeruli and the tubulointerstitial compartment [27] (Table 2) . They found an up-regulation of perlecan at the glomerular level, which was reduced in tubules. This proteoglycan inversely correlated with proteinuria and the progression of renal damage. These data suggest that the increased expression of perlecan in glomeruli may be considered a good prognostic biomarker for patients with IgAN because it plays a role in regenerating the structure and function of the matrix in glomeruli.
The gold standard for diagnosis of IgAN still remains renal biopsy analysis, based on the MEST score. The Oxford classification is based on four types of histological lesions: mesangial hypercellularity (M 0-1), endocapillary hypercellularity (E 0-1), segmental glomerulosclerosis (S 0-1) and tubular atrophy/interstitial fibrosis (T 0-1-2) [2, 31] . Hodgin et al. [28] evaluated the molecular phenotype of the E score by comparing the glomerular transcriptome of IgAN biopsies without endocapillary proliferation (E0, n ¼ 15) with biopsies with endocapillary proliferation (E1, n ¼ 7). They found 424 modulated genes involved in the innate immunity response, and in the inflammatory and T-cell signalling pathway; a subset of these transcripts, reported in Table 2 , correlated with the renal function at the time point of the biopsy. Interestingly, the authors integrated transcriptional data analysis with in silico drug signalling and identified new small molecules that are potentially helpful for reversing the pathological condition. This emerging integrative approach will be subject to greater focus later in this review.
Further transcriptomic studies could help to identify a molecular signature for the MEST lesions, and correlation with clinical data may clarify the mechanisms involved in the different renal stages of IgAN.
Reich et al. identified in vitro an 'albumin-regulated gene classifier' comparing differentially modulated genes in albumin-exposed tubular cells and normal tubular cells [29] . They subsequently conducted microarray analysis on fresh renal biopsies from patients with IgAN. These results were then compared with samples from living donors and 231 albuminregulated genes were found in IgAN, compared with the in vitro classifier. The albumin-regulated genes were then compared with other glomerulonephritis (FSGS, MCD and MN), and a set of 11 genes that relate to albumin exposure of the tubulointerstitial compartment, unique to IgAN, was identified, the socalled 'proteinuria signature'. The generated transcriptional network evidenced the EGR1 gene as the central node of the remaining 10 genes. All genes were implicated in the tubular response to proteinuria and promoted renal interstitial fibrosis. This result is interesting because it shows the direct effect of proteinuria on genes involved in tubular cell apoptosis and tubulointerstitial damage.
Recently, Wang and Cao [30] downloaded from GEO the microarray data deposited by Reich et al. [29] , and they processed the array data using a robust multi-chip average method. A total of 55 genes were differentially expressed in the tubular cells of IgAN patients compared with kidney biopsies from living donors. Three genes were up-regulated and 52 downregulated. The gene ontology analysis showed several significant functions of genes in the network, such as a response to steroid hormone stimulus and to some small molecules-particularly thapsigargin-that may reverse the disease. Therefore, this molecule should be taken into consideration for potential treatment of the disease.
In conclusion, different genes are expressed in kidney during the clinical course of IgAN. In the first stage, proteoglycan genes are upregulatd as a reaction to the immune complex deposition in the mesangial area [22] . Then, a subset of other genes is involved in glomerular lesions [28] and, finally, a pattern of genes is overexpressed at the tubular level in response to proteinuria thus causing tubulointerstitial damage [29, 30] . These data give additional information on the molecular pathogenic mechanism of kidney damage in IgAN.
LN. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by widespread loss of immune tolerance to self-antigen. The kidney is frequently affected, with heterogeneous glomerular damage involvement [6] . Biopsy-confirmed nephritis, with the presence of lupus autoantibodies, is now considered a 'stand-alone' criterion for LN diagnosis [32] .
Transcriptome analysis on LN has been conducted in murine lupus models [33] [34] [35] [36] [37] (Table 3 ). The MRL/lpr mouse represents the prototype model for SLE, and it spontaneously develops lethal renal disease, characterized by diffuse proliferative glomerulonephritis and interstitial nephritis [33] . Over 500 up-regulated genes have been found in microdissected glomeruli [34] . Corticosteroid therapy reduced the increased glomerular score and the overexpression of 130 genes that are involved in complement components, adhesion molecules, chemokines, chemokine receptors, antigen processing and presentation, extracellular matrix and related molecules, suggesting a strong linkage between monocyte and leukocyte infiltration and glomerular proliferative lesions. These data provide information on the benefit of corticosteroids through the modulation of overexpressed genes in murine LN [34] .
Another model for studying LN is the NZB/W mouse, which develops severe proliferative glomerulonephritis, progressive glomerulosclerosis and tubulointerstitial damage, as in human LN [35] . Transcriptomic data obtained from the renal cortex of NZB/W mice showed the presence of Duplan retrovirus-related transcripts in renal lesions, suggesting the involvement of the murine leukaemia retrovirus in the pathogenesis of LN [36] .
The gene-expression profile in human LN has been obtained from isolated glomeruli [42] (Table 3 ). All biopsies were stored at À80 C for periods ranging from several months to more than a year before being processed for microarray analyses. Only those biopsies that had been frozen within approximately 1 h of collection were suitable for microarray analysis, confirming the importance of fast treatment to preserve nucleic acid. Two independent sets of glomeruli were isolated by lasercapture microscopy. Four main gene clusters with increased expression were identified. The study identified the central role of infiltrating cells in the pathogenesis of LN, with the involvement of type I IFN-inducible genes expressed by activated NK cells.
Comparison of gene sets from three murine models of LN and human LN showed that infiltrating cells are the major culprits in the development of LN, particularly in the case of mononuclear phagocytic cells [37] . These data suggest that it is necessary to develop further research into experimental models for therapeutic implications. A limitation of this well-designed study is the small amount of tissue obtained from kidney biopsies, making it impossible to study the role of isolated cell populations in the pathogenesis of human LN.
DN.
Almost all the studies are derived from microdissected glomeruli, which represent the most affected tissue compartment in DN (Table 3) . Baelde et al. [38] conducted one of the first transcriptomic studies and compared gene-expression profiles of microdissected glomeruli from two DN and two control kidney specimens; data were then validated by RT-PCR and immunohistochemistry. They found significantly decreased levels of nephrin and vascular endothelial growth factor (VEGF) gene-expression. Later, Woroniecka et al. conducted geneexpression analysis on 22 microdissected human glomeruli and 22 tubules from patients with DN [39] . Their results showed 243 up-regulated transcripts in glomeruli compared with tubules. Some transcripts represented novel glomerular-specific genes, such as ARHGAP19, TCF21, IL13RA2 and CH13L1; five transcripts were exclusively expressed in the tubulointerstitial tissue. This analysis provided a compendium of glomerularand tubular-specific transcripts in DN, including many podocyte-specific genes and transcripts associated with inflammation and fibrosis.
A further transcriptomic study observed a decrease in VEGF-A expression in the microdissected tubulointerstitial compartment of DN patients. These results are relevant because they are in contrast to the increased renal VEGF-A expression found in some rodent models of DN, which highlights the importance of using human samples as well as animal models [40] .
However, as with LN, the basic research into DN has been driven by the use of several mouse models. The glomerular transcriptome from three murine models of DN has been compared with 22 kidney tissue biopsies of patients with early type 2 DN [41] . The human cohort was divided into two groups according to the average albumin/creatinine ratio at the time of biopsy. Hodgin et al. identified cross-species glomerular transcriptional networks that are shared between humans and mice; furthermore, they define specific gene networks involved in DN. More than one-third of the cross-species-conserved pathways overlapped between all three human-mouse comparisons. The transcriptomic changes in the murine models typically resembled the pattern observed in DN patients with microalbuminuria, rather than overt nephropathy. These results demonstrate that the detection of human-mouse shared glomerular transcripts might be of relevant interest in selecting mouse models that are similar to the human disease and that can be used to study the effect of novel drugs. Recently, a similar pattern of gene expression, which involved many pathways differentially expressed in the glomeruli of human DN, was observed in just one of the analysed murine models, implying that the choice of animal model can affect the research results [43] . Since an impressive quantity of data on the gene-expression profile of DN has been generated, almost all the pathways have been well summarized recently by Ni et al. [44] .
Currently, the considerable quantity of transcriptomic studies on renal biopsy in patients with DN shows that in the first stage of the disease podocyte genes (NPHS1, NPHS2, SYNPO, PODXL) are dysregulated. Then, other genes (COL1A2, COL3A1, VIM1, TIMP1 and TIMP3) are involved in the tubulointerstitial damage induced by albuminuria. These findings contribute to understand the molecular involvement of the renal damage in DM that will be used by systems pharmacology for targeted therapy.
D I S C U S S I O N
This review provides a summary of transcriptomic studies carried out in patients with primary and secondary glomerular diseases. Omics data have generated new insights into the pathogenetic mechanisms of these kidney diseases. Transcriptomic findings, reported in the Results section, demonstrate that progression of the renal damage is characterized by different sets of genes at glomerular and tubulointerstitial level. These genes may be considered potential targets for the precision therapy. However, additional improvements in methods and approaches are necessary, as follows. (i) Kidney biopsies are stored as frozen samples, but more often as FFPE samples. Frozen samples are limited in numbers because a kidney biopsy may provide two samples, where one is used for histology and the other for immunofluorescence. FFPE samples represent the greatest stock of archived samples, but provide highly fragmented RNA. Therefore, an improvement of molecular technologies may overcome this limitation. (ii) Transcriptomics may benefit greatly from integrated clinical and animal studies. (iii) The heterogeneity of data in omics studies suggests the need to validate potential diagnostic biomarkers in large cohorts of patients that are well stratified according to clinical and molecular findings. Many studies lack this type of validation. (iv) With access to kidney biopsies and to non-invasive biological fluids, such as urine, there is an opportunity to advance molecular knowledge and to make progress on precision nephrology. (v) Collaborative worldwide participation between all kidney biopsy biobanks will enable sharing of samples and datasets, and will provide an opportunity to define the key drivers of glomerular diseases.
Integration is the key to decoding the underlying principles that govern the complex functions of living systems. To integrate molecular data derived from omics technologies with results from clinical and histopathological studies might ultimately characterize renal diseases in a comprehensive and systematic manner, and improve the diagnosis and treatment of kidney diseases. Transcriptomics is the most widely used omics technique that can generate microarray-based diagnostic or prognostic assays in the clinical setting of native renal diseases and kidney transplantation in order to help develop precision medicine [45] .
Systems pharmacology is the key point for precision medicine because it identifies drugs that target disease-causing molecular pathways. By integrating multifaceted approaches, systems pharmacology can provide a mechanistic understanding of both the therapeutic and adverse effects of drugs [46] . Different bioinformatics tools allow the integration of gene-expression results with Food and Drug Administrationapproved drugs or existing bioactive compounds. This computational approach predicts the best drug combination that can revert a pathological condition by targeting disease-specific networks. Combination therapy using previously approved drugs could lead to safer and more efficient treatments.
In 2011, Fechete et al. [47] used data from five data sets (public omics, scientific literature, literature focus on biomarkers, patent and clinical trials) to identify pathway-specific biomarkers and therapy options for DN. Transcriptomics, proteomics, metabolomics and SNP studies were analysed. Molecular features were consolidated on a human protein interaction network and interpreted on the level of molecular pathways by considering the pathophysiology of the disease as well as the clinical-context layer. Protein-protein interaction networks were used for studying causative and associative dependencies of feature profiles. Three pathways appeared to be significantly affected, considering all five data sets: the reninangiotensin system, the complement and coagulation cascade and the PPAR signalling pathway. The DrugBank, a freely available tool, identified specific drugs linked to these pathways, according to a gene drug-assignment system.
The application of systems pharmacology in drug discovery is leading to the development of new computational methods. DrugComboRanker [48] and Drug Pair Seeker (DPS) [49] are examples of computational tools for drug-combination prediction. DPS was developed to predict and prioritize pairs of drugs using the Connectivity Map (CMAP) database. The CMAP database contains microarray signatures of gene expression derived from experiments that examined the effects of approximately 1300 single drugs on several human cancer cell lines. DPS can be used to analyse any set of mammalian up-and down-regulated genes. On the basis of the gene lists uploaded by users, the software identifies the potential drug combination that could reverse or aggravate the pathological condition [49] . Hodgin et al. [28] applied the DPS approach to identify bioactive compounds that modulated the transcripts in endocapillary proliferative lesions in IgAN biopsies. They found a set of predictive bioactive molecules that would reverse the transcriptional signature of E lesions, including methylprednisolone and resveratrol.
In conclusion, we highlight a new approach based on the integration of clinical and laboratory data with histological lesions and transcriptome. Additionally, systems pharmacology may contribute to the transition from conventional to precision therapy in nephrology.
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